The Incidence Of Prostate Cancer Higher In Men With Autoimmune Diseases PDF Print E-mail
Monday, 06 May 2013 22:05
Men with autoimmune diseases have a higher incidence of prostate cancer (PCa) than those without those diseases, according to study findings presented at the American Urological Association annual meeting.

Using the National Inpatient Sample database, researchers obtained data on 189,290 men with a history of autoimmune disease—multiple sclerosis (MS), systemic lupus erythematosus (SLE), systemic sclerosis, psoriasis, Sjogren's syndrome, discoid lupus erythematosus (DLE), or rheumatoid arthritis (RA)—and a subsequent diagnosis of PCa.

The investigators, led by Zachary Klaassen, MD, a urology resident at the Medical College of Georgia, Georgia Regents University, in Augusta, compared the age-specific incidence of PCa in this cohort with an external cohort of patients from the Surveillance, Epidemiology and End Results (SEER) database (2000-2009).

Compared with the general population, the incidence of PCa was three times greater for men with MS, five times greater for men with SLE, six times greater for men with systemic sclerosis, seven times greater for men with psoriasis, nine times greater for men with Sjogren's syndrome, 10 times greater for men with DLE, and 10 times greater for men with RA, according to the researchers.
Autoimmune disease affects 3.6 million to 5.9 million men in the U.S., Dr. Klaassen and his colleagues noted.

To their knowledge, the investigators said, their study is the first to suggest an increased incidence of PCa in men with autoimmune diseases.

Dr. Klaassen cautioned that the finding of an increased incidence of PCa may be due to increased screening of patients who, because of their autoimmune disease, may receive more intensive medical follow-up.

Source: Renal & Urology News (2013), "Prostate Cancer Incidence Higher in Men with Autoimmune Disease"; original article can be viewed here.

 
More articles :

» The Management and Treatment of Scleroderma is Improving

Management of systemic sclerosis is likely to improve as soon as an ongoing convergence of mechanistic insights, improved understanding of clinical trial design, and interest by industry results in new treatments, according to Dr. Robert F....

» DETECT Algorithm Increases Rate Of Diagnosis For PAH In Scleroderma Patients

The use of a two-step algorithm significantly increased the rate at which pulmonary arterial hypertension was diagnosed in patients with in a prospective, observational, cross-sectional study. The results of the , presented at the annual European...

» Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in...

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...

» Thoracic Outlet Syndrome Secondary to Localized Scleroderma Treated With Botulinum Toxin Injection

Localized scleroderma is characterized by thickening of the skin and subcutaneous tissue. Depending on clinical and pathologic findings, localized scleroderma is classified into different subtypes: plaque morphea, generalized morphea, bullous...

» Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

Tamiko R. Katsumoto, Shelia M. Violette, and Dean SheppardReceived 27 May 2011; Accepted 15 August 2011Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of...